You can buy or sell BeiGene and other stocks, options, ETFs, and crypto commission-free!
BeiGene, Ltd. American Depositary Shares, also called BeiGene, is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. Read More It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
52 Week High
52 Week Low
Yahoo FinanceMay 9
BRIEF-BeiGene Q1 Loss Per Share $0.22
May 9 (Reuters) - Beigene Ltd: * BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS * Q1 LOSS PER SHARE $0.22 * COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 MILLION FOR SAME PERIOD IN 2018 * QTRLY LOSS PER SHARE $0.22 Source text for Eikon: Further company coverage:...
Yahoo FinanceMay 9
BeiGene Reports First Quarter 2019 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, May 09, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights, anticipated upcoming milestones and financial results for the first quarter of 2019. “We made good progress in each of our business areas, including strong commercial performance ...
Yahoo FinanceMay 8
BeiGene Says China's Pharma Industry Going Through Positive Changes
May.08 -- John Oyler, chief executive officer of BeiGene, a Chinese cancer-drug developer, talks about the outlook for the industry and the company's strategy. BeiGene had it secondary listing in Hong Kong in August 2018 after debuting in New York in 2016. He speaks on the sidelines of J.P.Morgan:s 15th Global China Summit in Beijing on "Bloomberg Daybreak: Asia."...
Expected Aug 9, After Hours